Formoterol furmarate (20 μg)

DRUG2 trials

Sponsors

AstraZeneca, Medical University of South Carolina

Conditions

Chronic Obstructive Pulmonary Disease - COPDDiabetic Kidney DiseaseDiabetic Nephropathies

Phase 2

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

CompletedNCT02796651

AstraZenecaChronic Obstructive Pulmonary Disease - COPD

Start: 2016-06-30End: 2016-12-07Updated: 2018-02-07

Formoterol in Diabetes

RecruitingNCT07022418

Medical University of South CarolinaDiabetic Kidney Disease, Diabetic Nephropathies

Start: 2025-12-01End: 2027-11-01Target: 120Updated: 2026-02-05